MINOX SOLUTION

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

MINOXIDIL

Fáanlegur frá:

LABORATOIRE RIVA INC.

ATC númer:

D11AX01

INN (Alþjóðlegt nafn):

MINOXIDIL, TOPICAL

Skammtar:

20MG

Lyfjaform:

SOLUTION

Samsetning:

MINOXIDIL 20MG

Stjórnsýsluleið:

TOPICAL

Einingar í pakka:

250ML

Gerð lyfseðils:

OTC

Lækningarsvæði:

MISC. SKIN AND MUCOUS MEMBRANE AGENTS

Vörulýsing:

Active ingredient group (AIG) number: 0114429001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2022-09-29

Vara einkenni

_MINOX (Minoxidil Topical Solution) _
_Page 1 of 33_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MINOX
Minoxidil Topical Solution
20 mg/mL (2% w/v)
USP
Hair Regrowth Treatment
THIS PRODUCT IS FOR MEN ONLY
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Date of Initial Authorization:
August 19, 1996
Date of Revision:
August 4, 2022
Submission Control Number: 263345
_MINOX (Minoxidil Topical Solution) _
_Page 2 of 33_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.4
Administration...................................................................................................
5
4.5
Missed Dose
......................................................................................................
6
5
OVERDOSAGE
.............................................................................................................
6
6
DOSAGE FORMS, STRENGTHS, COMPOSI